Senti BiosciencesSNTI
Market Cap: $14.4M
About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Employees: 48
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
121% more capital invested
Capital invested by funds: $4.15M [Q1] → $9.17M (+$5.02M) [Q2]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
1.32% less ownership
Funds ownership: 24.03% [Q1] → 22.71% (-1.32%) [Q2]
26% less funds holding
Funds holding: 27 [Q1] → 20 (-7) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Research analyst outlook
We haven’t received any recent analyst ratings for SNTI.